Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis

Ophthalmology

Volumn 119, Issue 2, 2012, Pages 327-332

  Cionni, Douglas A ^a   Lewis, Shawn A ^a,b   Petersen, Michael R ^a   Foster, Robert E ^a   Riemann, Christopher D ^a,b   Sisk, Robert A ^a,b   Hutchins, Robert K ^a,b   Miller, Daniel M ^a,b  

^a CINCINNATI EYE INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; ARTICLE; CHOROID; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HISTOPLASMOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; PRESUMED OCULAR HISTOPLASMOSIS SYNDROME; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; EYE INFECTIONS, FUNGAL; FEMALE; FOLLOW-UP STUDIES; HISTOPLASMOSIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84856515625     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.08.032     Document Type: Article

References (30)

1. R.J. Olk, S.L. Fine, D. Scherage Long-term follow-up of ocular histoplasmosis treated by argon laser photocoagulation Retina 1 1981 238 244
2. Macular Photocoagulation Study Group Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial Arch Ophthalmol 105 1987 1499 1507
3. T.A. Meredith, W.R. Green, S.N. Key Ocular histoplasmosis: clinicopathologic correlation of 3 cases Surv Ophthalmol 22 1977 189 205 (Pubitemid 8234638)
4. J.P. Ganley Epidemiologic characteristics of presumed ocular histoplasmosis Acta Ophthalmol Suppl 119 1973 1 63
5. T.A. Makley Jr, E. Craig, J. Long Histopathology of presumed ocular histoplasmosis Palestra Oftalmol Panam 1 1977 72 82
6. J.V. Ongkosuwito, L.M. Kortbeek, A. Van der Lelij Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands Br J Ophthalmol 83 1999 535 539 (Pubitemid 29213124)
7. F.G. Bottoni, A.F. Deutman, A.L. Aandekerk Presumed ocular histoplasmosis syndrome and linear streak lesions Br J Ophthalmol 73 1989 528 535 (Pubitemid 19184502)
8. W.H. Spencer, C.C. Chan, D.F. Shen, N.A. Rao Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome Arch Ophthalmol 121 2003 1551 1555 (Pubitemid 37392357)
9. J.P. Ganley, R.E. Smith The natural history of non-disciform ocular histoplasmosis Can J Ophthalmol 12 1977 114 120 (Pubitemid 8106191)
10. Macular Photocoagulation Study Group Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial Arch Ophthalmol 101 1983 1347 1357
11. D.A. Saperstein, P.J. Rosenfeld, N.M. Bressler Verteporfin in Ocular Histoplasmosis (VOH) Study Group Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series Ophthalmology 109 2002 1499 1505
12. P.J. Rosenfeld, D.A. Saperstein, N.M. Bressler Verteporfin in Ocular Histoplasmosis (VOH) Study Group Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study Ophthalmology 111 2004 1725 1733 (Pubitemid 39179689)
13. A. Almony, M.A. Thomas, N.H. Atebara Long-term follow-up of surgical removal of extensive peripapillary choroidal neovascularization in presumed ocular histoplasmosis syndrome Ophthalmology 115 2008 540 545
14. R. Schadlu, K.J. Blinder, G.K. Shah Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis Am J Ophthalmol 145 2008 875 878
15. A.M. Mansour, F. Mackensen, J.F. Arevalo Intravitreal bevacizumab in inflammatory ocular neovascularization Am J Ophthalmol 146 2008 410 416
16. M.N. Lott, J.C. Schiffman, J.L. Davis Bevacizumab in inflammatory eye disease Am J Ophthalmol 148 2009 711 717
17. Q.D. Nguyen, S.M. Shah, G. Hafiz Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration Am J Ophthalmol 145 2008 257 266
18. R. Erlich, T.A. Ciulla, R. Maturi Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome Retina 29 2009 1418 1423
19. A. Adan, C. Mateo, R. Navarro Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization Retina 27 2007 1180 1186 (Pubitemid 350211522)
20. A. Pece, M. Vadala, V. Isola, D. Matranga Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study Am J Ophthalmol 143 2007 449 454
21. M.A. Busquets, G.K. Shah, J. Wickens Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome Retina 23 2003 299 306 (Pubitemid 36792973)
22. L. Arias, J. Garcia-Arumi, J.M. Ramon Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study Ophthalmology 113 2006 2243 2250 (Pubitemid 44838921)
23. Verteporfin in Photodynamic Therapy (VIP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trialVIP report no. 3 Ophthalmology 110 2003 667 673
24. A.H. Rogers, J.S. Duker, N. Nichols, B.J. Baker Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults Ophthalmology 110 2003 1315 1320 (Pubitemid 36842464)
25. A.M. Mansour, J.F. Arevalo, F. Ziemssen Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization Am J Ophthalmol 148 2009 310 316
26. S.J. Bakri, S.M. Couch, C.A. McCannel, A.O. Edwards Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration Retina 29 2009 573 578
27. P.K. Kaiser Registry of Visudyne AMD Therapy Writing Committee Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Ophthalmology 116 2009 747 755
28. C. Costagliola, M.R. Romano, M. Rinaldi Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Br J Ophthalmol 94 2010 180 184
29. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study Am J Ophthalmol 148 2009 43 58
30. W.E. Smiddy Economic implications of current age-related macular degeneration treatments Ophthalmology 116 2009 481 487